Mentions
Extended reach
Total likes
Video views
AI synopsis
The group collectively emphasizes the clinical superiority of racemic ketamine over esketamine, frequently quoting phrases like "intravenous ketamine is more effective" and discussing economic benefits of off-patent options, which reflects a deep engagement with both scientific evidence and practical implications.
Most discussions support the finding that racemic ketamine is more effective than esketamine, emphasizing the superiority of intravenous administration in the responses.
The discussions demonstrate high interest, with multiple references to clinical trials, routes of administration, and economic implications, indicating a focus on the topic.
Participants are actively engaging through quoting studies, debating the efficacy of different routes, and suggesting improvements, showing thoughtful involvement.
The discussions highlight potential shifts in treatment approaches and policy changes, reflecting significant implications for medical practice and drug repurposing.
The cost of one new drug exceeds the $3b MC of @BoredApeYC. $100m in Open Ketamine NFTs can retroactively fund successful clinical trials for off-patent ketamine, arguably treating depression better than patented sketamine https://t.co/rqLXmylTPe @psy_dao @Molecule_dao @lab_dao https://t.co/qedSYdFXMi
Comparative efficacy of racemic #ketamine and #esketamine for #depression: A systematic review and meta-analysis.https://t.co/lWSmMHSMrC #nursepractitioner #mentalhealth #psychiatry #mhchat #mh #medicine #primarycare #TRD https://t.co/p39dVsetKx
@martincodyre @singareddynm @newzealandlaw We can fix perverse incentives with contracts - we can recruit esketamine patients into interventional pharmacoeconomic RCTs that are paid out of cost savings by randomising 50% of patients to receive ketamine instead (which is arguably more effective https://t.co/rqLXmymrEM).
@MorganGodvin The meta-analysis study concludes "Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression" - but that's conflating different routes of use with different types of ketamine. https://t.co/DEfh0vGGKo
(1/2) To date, there's limited clinical evidence proving that es-ketamine [the patented left-hand molecule of ketamine] is more helpful in treating major depression than racemic (generic) ketamine. Many clinical trials show the generic is more effective. https://t.co/O2FfwE1wic
RT @GlobalMedEd: Comparative efficacy of racemic #ketamine and #esketamine for #depression: A systematic review and meta-analysis.https://t…
Spravato, an intranasal esketamine, is FDA-approved for depression treatment and insurance-covered. This video compares its effectiveness to generic racemic ketamine infusions based on recent research, highlighting…
Depression affects millions globally, and traditional treatments often don't work for some. This video explores esketamine, a nasal spray derived from ketamine, which provides rapid relief by targeting the NMDA…
This systematic review compares the efficacy of racemic ketamine and esketamine for depression, indicating racemic ketamine's higher response and remission rates. The study analyzed data from 24 trials with 1,877…
@MelissaBou12321 @VolodimirZelen1 9/10 : Suite des sources : Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis : https://t.co/DotlHk3fVp
@AllenFrancesMD What you refer to is the nasal administration of esketamine. However, intravenous ketamine is more effective. https://t.co/4YYulxUvHI
Some more references: https://t.co/CqAEQXFheP https://t.co/jSSnXpKBtn https://t.co/5lFpfI3IYS
@MorganGodvin The meta-analysis study concludes "Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression" - but that's conflating different routes of use with different types of ketamine. https://t.co/DEfh0vGGKo
@SpacedOutMatt @goth600 First review article I found: “Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.” https://t.co/pAnyvxsJoq
@martincodyre @singareddynm @newzealandlaw We can fix perverse incentives with contracts - we can recruit esketamine patients into interventional pharmacoeconomic RCTs that are paid out of cost savings by randomising 50% of patients to receive ketamine instead (which is arguably more effective https://t.co/rqLXmymrEM).
(1/2) To date, there's limited clinical evidence proving that es-ketamine [the patented left-hand molecule of ketamine] is more helpful in treating major depression than racemic (generic) ketamine. Many clinical trials show the generic is more effective. https://t.co/O2FfwE1wic
RT @CrowdFundedCure: The cost of one new drug exceeds the $3b MC of @BoredApeYC. $100m in Open Ketamine NFTs can retroactively fund succes…
RT @CrowdFundedCure: The cost of one new drug exceeds the $3b MC of @BoredApeYC. $100m in Open Ketamine NFTs can retroactively fund succes…
The cost of one new drug exceeds the $3b MC of @BoredApeYC. $100m in Open Ketamine NFTs can retroactively fund successful clinical trials for off-patent ketamine, arguably treating depression better than patented sketamine https://t.co/rqLXmylTPe @psy_dao @Molecule_dao @lab_dao https://t.co/qedSYdFXMi
@HamiltonMorris Although, Racemic Ketamine is superior to Esketamine in clinical response and remission rates in depression. https://t.co/MJ5mwFLCcA And https://t.co/uXqkFjbzsy
RT @GlobalMedEd: Comparative efficacy of racemic #ketamine and #esketamine for #depression: A systematic review and meta-analysis.https://t…
RT @GlobalMedEd: Comparative efficacy of racemic #ketamine and #esketamine for #depression: A systematic review and meta-analysis.https://t…
Comparative efficacy of racemic #ketamine and #esketamine for #depression: A systematic review and meta-analysis.https://t.co/lWSmMHSMrC #nursepractitioner #mentalhealth #psychiatry #mhchat #mh #medicine #primarycare #TRD https://t.co/p39dVsetKx
@juliaskripkaser @Aesculapius1898 ok, found the biology part on this! https://t.co/Hhk0qZwHrk
Another meta-analysis last September compared both versions of ketamine more directly and favored racemix https://t.co/GSp2YRSCbN As did this review this March https://t.co/0UzEAapALd
Letter to the editor – Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis https://t.co/9rtNoXX0PN
@PsychToday @DrRaymondLam @ArashEmamzadeh https://t.co/oYZZCz3Wfd
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis - ScienceDirect https://t.co/6pWbS1pnRv